NASDAQ: SMMTSummit Therapeutics Inc Stock
$3.59-0.14 (-3.75%)
Updated Apr 24, 2024
SMMT Price
$3.59
Fair Value Price
-$0.07
Market Cap
$2.52B
52 Week Low
$1.30
52 Week High
$5.22
P/E
-359x
P/B
32.42x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$614.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.61
Operating Cash Flow
-$77M
Beta
0.47
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SMMT Overview
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SMMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SMMT ($3.59) is overvalued by 5,253.68% relative to our estimate of its Fair Value price of -$0.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SMMT ($3.59) is not significantly undervalued (5,253.68%) relative to our estimate of its Fair Value price of -$0.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SMMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SMMT due diligence checks available for Premium users.
Be the first to know about important SMMT news, forecast changes, insider trades & much more!
SMMT News
Valuation
SMMT fair value
Fair Value of SMMT stock based on Discounted Cash Flow (DCF)
Price
$3.59
Fair Value
-$0.07
Undervalued by
5,253.68%
SMMT ($3.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SMMT ($3.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SMMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SMMT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-359x
Industry
15.69x
Market
41.27x
SMMT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
32.42x
Industry
5.86x
SMMT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SMMT's financial health
Profit margin
Revenue
$0.0
Net Income
-$36.6M
Profit Margin
0%
SMMT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$202.9M
Liabilities
$125.3M
Debt to equity
1.61
SMMT's short-term assets ($189.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SMMT's short-term assets ($189.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SMMT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SMMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.5M
Investing
$60.6M
Financing
$6.3M
SMMT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SMMT vs Biotech Stocks
Summit Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.